Safety and Tolerability of Cannabidiol in Subjects With Drug Resistant Epilepsy
Status:
Approved for marketing
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This is an observational, open-label, flexible dose study that will prospectively and
longitudinally assess the effect of Cannabidiol (CBD) therapy in patients with drug-resistant
epilepsies through a Physician Expanded Access Investigational New Drug protocol.
Details
Lead Sponsor:
Christopher J. Kratochvil, M.D. Deepak Madhavan MD